Jazz Pharmaceuticals agreed to acquire Actio Biosciences for $820 million upfront, with additional milestone payments of up to $500 million tied to performance for its ultra-rare epilepsy drug. The deal underscores continued consolidation in orphan neurology as companies look to broaden clinical-stage exposure and reduce platform risk. Jazz framed the transaction as a way to strengthen its presence in epilepsy by bringing Actio’s asset into its development pipeline. For Actio, the agreement provides near-term liquidity while shifting execution responsibility to a larger platform. The pricing and milestone structure also signals that investors and boards expect measurable clinical progress to drive subsequent valuation—making upcoming data points decisive for whether the combined portfolio translates into long-term registrational and commercial outcomes.